USMLE Step 1 general pharmacology & autonomic drugs questions

A noncompetitive (irreversible or allosteric) antagonist binds to the receptor in a manner that cannot be displaced by increasing agonist concentration, so it reduces the maximal effect (Emax) that the agonist can produce. This is in contrast to a competitive antagonist, which shifts the EC50 to the right (decreasing potency) but does not lower Emax because enough agonist can still outcompete the antagonist. The irreversible binding described here, with no restoration of Emax despite adding more Drug X, is the hallmark of noncompetitive antagonism.

• B. A physiologic antagonist acts at a different receptor on a different pathway, not at the same receptor site.
• C. A partial agonist would itself produce some intrinsic effect and would not irreversibly block the receptor.
• D. This describes an agonist or positive allosteric modulator, not an antagonist that lowers Emax.
• E. A competitive antagonist decreases potency (rightward shift) but does not lower the maximal achievable effect.

A partial agonist has lower intrinsic efficacy than a full agonist, even if it binds the same receptor with similar or even higher affinity. When a partial agonist occupies a significant fraction of receptors, it prevents the full agonist from binding those receptors, and because the partial agonist cannot activate the receptor to the same maximal degree as the full agonist, the overall achievable effect is reduced below that of the full agonist alone. This is distinct from potency, which refers to the dose needed to produce a given effect, not the maximal effect itself.

• B. Potency differences alone would shift the dose-response curve but would not explain a reduced ceiling effect when both drugs occupy the same receptors.
• C. The scenario describes a pharmacodynamic interaction at the receptor level, not a pharmacokinetic change in morphine metabolism.
• D. A pure competitive antagonist with zero intrinsic activity would produce no analgesia on its own, which contradicts the finding that Drug Z alone has some effect.
• E. A full agonist with higher affinity would not reduce the maximal effect; it would simply outcompete morphine without lowering Emax.

Potency refers to the concentration (or dose) required to produce a given effect, typically expressed as the EC50 (or ED50); a lower EC50 indicates greater potency. Drug M requires only 10 nM to achieve 50% of its maximal effect, compared with 100 nM for Drug N, so Drug M is more potent. Efficacy refers to the maximal effect a drug can produce (Emax); since both drugs reach the same maximal relaxation of 90%, they have equal efficacy despite their difference in potency.

• A. Potency is not equal between the two drugs, since their EC50 values differ by a factor of ten.
• B. Efficacy (Emax) is identical for both drugs at 90%, and potency is not equal since their EC50 values differ.
• D. The drugs do not have equal potency; Drug M requires a tenfold lower concentration to reach 50% of maximal effect.
• E. Drug N is less potent, not more potent, because it requires a higher concentration to reach the same effect, and efficacy is equal between the two drugs.

Rifampin is a potent inducer of hepatic cytochrome P450 enzymes, particularly CYP3A4, which increases the transcription and synthesis of these enzymes over days to weeks. This enhanced enzymatic activity accelerates the metabolism and clearance of ethinyl estradiol and other CYP3A4 substrates, lowering their plasma concentrations below the threshold needed for reliable contraceptive efficacy. Patients taking enzyme-inducing drugs such as rifampin, carbamazepine, or phenytoin should be counseled to use alternative or additional contraceptive methods.

• A. Protein-binding displacement is not the mechanism of this interaction and would not meaningfully increase drug clearance.
• C. Rifampin induces, rather than inhibits, CYP450 enzymes, and the result is increased, not decreased, active drug metabolism.
• D. The interaction is primarily hepatic (enzyme induction leading to increased metabolism), not renal clearance.
• E. Rifampin's clinically important interaction with oral contraceptives occurs via hepatic enzyme induction, not through direct binding or inhibition of absorption in the gut.

Clarithromycin, like other macrolides, is a potent inhibitor of CYP3A4, the enzyme primarily responsible for metabolizing simvastatin. Inhibition of this enzyme decreases simvastatin's hepatic clearance, causing accumulation of the active drug and dramatically raising its plasma concentration. This leads to statin-induced myopathy and rhabdomyolysis, presenting with muscle pain, weakness, markedly elevated creatine kinase, and acute kidney injury from myoglobin-induced tubular damage. Statins metabolized by CYP3A4 (simvastatin, lovastatin, atorvastatin) should be avoided or dose-reduced with strong CYP3A4 inhibitors.

• A. Clarithromycin inhibits rather than induces CYP3A4, and simvastatin toxicity results from reduced clearance of the parent/active drug, not formation of a toxic metabolite via induction.
• B. P-glycoprotein effects on absorption are not the principal mechanism of this interaction; CYP3A4 inhibition affecting hepatic metabolism is.
• D. Glucuronidation (phase II) is not simvastatin's primary metabolic pathway; CYP3A4-mediated oxidation (phase I) is.
• E. Protein-binding displacement and altered renal excretion are not the mechanism of this well-described hepatic enzyme interaction.

Isoniazid is metabolized primarily by hepatic N-acetyltransferase 2 (NAT2), and genetic polymorphisms produce 'slow acetylator' phenotypes with reduced NAT2 activity, which are common in certain populations including those of Middle Eastern and North African descent. Slow acetylators accumulate higher plasma concentrations of isoniazid, which increases the risk of peripheral neuropathy because isoniazid interferes with pyridoxine (vitamin B6) metabolism, impairing synthesis of neurotransmitters and myelin components. This is why pyridoxine supplementation is routinely given with isoniazid, particularly in patients at risk of slow acetylation, malnutrition, or alcoholism.

• A. Increased, not decreased, NAT2 activity would accelerate isoniazid clearance and protect against toxicity, the opposite of the slow acetylator phenotype causing neuropathy.
• C. CYP3A4 is not the primary enzyme responsible for isoniazid metabolism, and the neuropathy mechanism relates to pyridoxine depletion, not direct demyelination.
• D. Isoniazid metabolism is governed by NAT2 acetylation, not CYP2D6, and this option describes an unrelated and incorrect pathway.
• E. Glucuronidation is not the principal pathway for isoniazid clearance; NAT2-mediated acetylation is.

Phase I reactions (oxidation, reduction, hydrolysis), largely mediated by hepatic cytochrome P450 enzymes, are more sensitive to the effects of aging, cirrhosis, and reduced hepatic blood flow than Phase II reactions (glucuronidation, sulfation, acetylation, glycine conjugation). This is because Phase II conjugating enzyme activity is relatively well preserved even in the setting of hepatocellular dysfunction. Clinically, this means drugs that rely on Phase I oxidative metabolism, like diazepam, can accumulate and cause toxicity in elderly or cirrhotic patients, whereas drugs that undergo direct Phase II conjugation, like lorazepam, oxazepam, and temazepam, are metabolized more reliably and are preferred in these populations.

• B. This reverses the actual relationship; Phase I, not Phase II, reactions are preferentially impaired in aging and liver disease.
• C. Both phase I and phase II reactions occur predominantly in the liver (and other tissues), not segregated between kidney and liver.
• D. Phase I and Phase II reactions are not equally affected; Phase I oxidative metabolism declines disproportionately in these conditions.
• E. Phase II reactions typically produce inactive, more water-soluble metabolites for excretion, not more active ones; Phase I reactions can produce active or toxic metabolites.

Alpha-1 receptors couple to Gq proteins, which activate phospholipase C. PLC cleaves PIP2 into IP3 and DAG. IP3 releases calcium from the sarcoplasmic/endoplasmic reticulum, and DAG activates protein kinase C, together increasing intracellular calcium and causing smooth muscle contraction, as in vasoconstriction.

• A. Beta-1 receptors couple to Gs and increase cAMP via adenylyl cyclase, not the IP3/DAG pathway.
• B. Beta-2 receptors also couple to Gs and increase cAMP, causing smooth muscle relaxation rather than contraction.
• C. D1 receptors couple to Gs and increase cAMP, not phospholipase C activity.
• D. M2 receptors couple to Gi, decreasing cAMP, and are found mainly in cardiac tissue.

Beta-1 receptors are coupled to Gs proteins, which stimulate adenylyl cyclase to increase cAMP production. Elevated cAMP activates protein kinase A, which phosphorylates L-type calcium channels (increasing calcium influx and contractility) and phospholamban (speeding calcium reuptake and relaxation). This pathway underlies the positive inotropic and chronotropic effects of beta-1 stimulation in the heart.

• A. Nicotinic receptors are ligand-gated ion channels, not G-protein coupled receptors.
• B. Alpha-1 receptors couple to Gq and activate phospholipase C, not adenylyl cyclase.
• C. Alpha-2 receptors also couple to Gi, decreasing cAMP rather than increasing it.
• E. M2 receptors couple to Gi, which inhibits adenylyl cyclase and decreases cAMP, opposite to the described effect.

M3 muscarinic receptors on bladder detrusor and gastrointestinal smooth muscle couple to Gq, activating phospholipase C and generating IP3/DAG. The resulting rise in intracellular calcium binds calmodulin, which activates myosin light-chain kinase, promoting smooth muscle contraction. This mechanism underlies the use of direct muscarinic agonists like bethanechol for urinary retention and the parasympathetic promotion of GI motility.

• A. Beta-2 receptors couple to Gs, increasing cAMP and causing smooth muscle relaxation, not contraction.
• B. Nicotinic receptors are ligand-gated ion channels found at autonomic ganglia and neuromuscular junctions, not Gq-coupled smooth muscle receptors.
• C. M2 receptors predominate in cardiac tissue and couple to Gi, decreasing cAMP and heart rate rather than causing smooth muscle contraction via Gq.
• E. Alpha-2 receptors couple to Gi and primarily mediate presynaptic autoinhibition of norepinephrine release, not detrusor contraction.

Presynaptic alpha-2 adrenergic receptors on sympathetic nerve terminals act as autoreceptors that sense released norepinephrine and couple to Gi proteins, inhibiting adenylyl cyclase and lowering cAMP. This reduces presynaptic calcium influx and vesicle fusion, decreasing further norepinephrine release as a negative feedback loop. Clonidine and other alpha-2 agonists exploit this receptor centrally to reduce sympathetic outflow.

• A. M3 receptors are postsynaptic Gq-coupled receptors on smooth muscle and glands, unrelated to noradrenergic presynaptic feedback.
• B. Beta-2 receptors also couple to Gs and are mainly postsynaptic on smooth muscle, not involved in presynaptic autoinhibition.
• C. Beta-1 receptors couple to Gs and are primarily postsynaptic on cardiac tissue, increasing rather than inhibiting neurotransmitter release pathways.
• D. Alpha-1 receptors are postsynaptic and couple to Gq, mediating smooth muscle contraction rather than presynaptic feedback inhibition.

Nicotinic receptors (receptor A) are ionotropic ligand-gated ion channels composed of five subunits arranged around a central pore; acetylcholine binding directly opens the channel, producing fast excitatory postsynaptic responses, as at the neuromuscular junction and autonomic ganglia. Muscarinic receptors (receptor B) are metabotropic G-protein coupled receptors with seven transmembrane domains that require intracellular signal transduction (via Gq, Gi, or Gs depending on subtype) before producing a cellular effect, resulting in a slower onset and offset of action.

• A. Muscarinic receptors are GPCRs, but nicotinic receptors are not GPCRs; they are ligand-gated channels.
• B. Nicotinic receptors are ion channels, but muscarinic receptors are not ion channels at all; they are GPCRs.
• C. This reverses the actual structures: nicotinic receptors are the ion channels and muscarinic receptors are the GPCRs.
• E. This reverses the mechanisms: the nicotinic receptor directly gates an ion channel, while the muscarinic receptor requires a second messenger cascade.

Bethanechol is a direct-acting muscarinic agonist that is resistant to acetylcholinesterase degradation because it lacks an ester bond susceptible to the enzyme, giving it a longer duration of action than acetylcholine. It selectively stimulates M3 receptors on bladder detrusor and gastrointestinal smooth muscle, making it useful for postoperative or neurogenic urinary retention and ileus when there is no mechanical obstruction. Pilocarpine, another direct muscarinic agonist, is instead favored for ophthalmic use (glaucoma, Sjogren syndrome dry mouth) due to its ability to cross tissue barriers rapidly.

• A. Scopolamine is a muscarinic antagonist used for motion sickness, which would worsen rather than treat urinary retention.
• B. Neostigmine is an indirect-acting acetylcholinesterase inhibitor used mainly for myasthenia gravis and reversal of neuromuscular blockade; bethanechol's direct action and resistance to esterase degradation make it preferred for isolated bladder atony.
• C. Pilocarpine is a direct muscarinic agonist but is used topically for glaucoma and xerostomia, not for systemic bladder stimulation.
• D. Atropine is a muscarinic antagonist that would worsen urinary retention, not treat it.

Neostigmine is a reversible acetylcholinesterase inhibitor that prevents the breakdown of acetylcholine in the synaptic cleft, raising its concentration at the neuromuscular junction. This increased acetylcholine competes with and displaces nondepolarizing neuromuscular blockers like rocuronium from nicotinic receptors, restoring neuromuscular transmission. Because neostigmine also increases acetylcholine at muscarinic receptors systemically, an antimuscarinic agent such as glycopyrrolate is co-administered to prevent bradycardia, bronchospasm, and excessive secretions.

• B. Choline acetyltransferase synthesizes acetylcholine from choline and acetyl-CoA; neostigmine does not act on this enzyme.
• C. Neostigmine does not act on presynaptic calcium channels or directly affect vesicle release.
• D. Neostigmine does not directly bind nicotinic receptors; it acts indirectly by preserving acetylcholine levels.
• E. There is no significant presynaptic acetylcholine reuptake transporter analogous to monoamine reuptake; choline, not acetylcholine, is recycled via a separate transporter, and this is not neostigmine's mechanism.

Physostigmine is a tertiary amine acetylcholinesterase inhibitor that is lipophilic enough to cross the blood-brain barrier, allowing it to reverse both the central nervous system manifestations (agitation, delirium) and peripheral muscarinic deficits of anticholinergic toxicity. It is reserved for severe, refractory anticholinergic delirium because of risks of seizures and bradyarrhythmias, and is given with cardiac monitoring. Quaternary amine cholinesterase inhibitors cannot cross the blood-brain barrier and therefore only address peripheral symptoms.

• A. Neostigmine is a quaternary amine that does not cross the blood-brain barrier, so it cannot reverse central anticholinergic symptoms like delirium.
• B. Pyridostigmine is also a quaternary amine with poor CNS penetration, used mainly for chronic myasthenia gravis management rather than acute anticholinergic toxicity.
• C. Edrophonium is a short-acting quaternary amine cholinesterase inhibitor used diagnostically for myasthenia gravis, not for anticholinergic toxidrome reversal, and does not cross the blood-brain barrier.
• D. Bethanechol is a direct muscarinic agonist, not a cholinesterase inhibitor, and does not cross the blood-brain barrier to address central toxicity.

Norepinephrine is a potent alpha-1 and beta-1 agonist with minimal beta-2 activity, so it raises mean arterial pressure through intense vasoconstriction. The resulting rise in arterial pressure activates carotid and aortic baroreceptors, increasing vagal (parasympathetic) outflow to the sinoatrial node. This reflex bradycardia opposes the drug's direct positive chronotropic effect on beta-1 receptors, so the net heart rate can fall despite a cardiac stimulant being infused. Epinephrine at low doses causes less reflex bradycardia because beta-2-mediated vasodilation blunts the rise in diastolic pressure.

• A. Epinephrine is not the drug described, and catecholamines do not directly inhibit the SA node.
• B. Norepinephrine does not act on muscarinic receptors; the bradycardia is reflex, not direct.
• C. Receptor desensitization occurs over hours to days of exposure, not within minutes.
• E. Norepinephrine has negligible beta-2 activity, so this is not the mechanism of the pressor effect or the bradycardia.

Phenylephrine is a selective alpha-1 adrenergic agonist with minimal activity at alpha-2, beta-1, or beta-2 receptors. Alpha-1 receptors couple to Gq proteins, activating phospholipase C to generate IP3 and diacylglycerol, which raises intracellular calcium and causes vascular smooth muscle contraction. In the nasal mucosa this produces vasoconstriction, reducing blood flow and mucosal edema, which relieves congestion. Because it lacks beta activity, phenylephrine does not significantly raise heart rate at typical oral decongestant doses, though higher parenteral doses are used as a vasopressor.

• A. Alpha-1 receptors are G protein-coupled, not ligand-gated ion channels.
• B. Cyclic GMP signaling is characteristic of nitric oxide/natriuretic peptide pathways, not adrenergic receptors.
• C. Gi-mediated decreased cAMP describes alpha-2 receptor signaling, not alpha-1.
• E. This Gs/cAMP pathway describes beta-adrenergic receptor signaling, not alpha-1.

Albuterol (short-acting) and salmeterol (long-acting) are both beta-2 adrenergic agonists that activate Gs-coupled receptors on bronchial smooth muscle, increasing cAMP via adenylyl cyclase. Elevated cAMP activates protein kinase A, which inhibits myosin light-chain kinase, reducing calcium sensitivity and promoting smooth muscle relaxation and bronchodilation. Salmeterol's long lipophilic tail allows it to remain anchored in the receptor's lipid-rich microenvironment, producing a slow onset but duration of action up to 12 hours, making it suitable for maintenance therapy rather than acute attacks. Albuterol has a shorter, less lipophilic structure, giving rapid onset ideal for rescue use.

• B. Muscarinic antagonism describes drugs like ipratropium and tiotropium, not beta-2 agonists.
• C. Leukotriene receptor antagonists like montelukast act by a different mechanism entirely.
• D. Beta-2 receptors signal through Gs/cAMP, not Gq/phospholipase C.
• E. Phosphodiesterase inhibitors like theophylline raise cAMP by blocking its breakdown, not by receptor agonism.

Dobutamine is a synthetic catecholamine that acts predominantly on beta-1 receptors in the myocardium, increasing contractility (positive inotropy) and heart rate with relatively little effect on alpha-1-mediated vasoconstriction or beta-2-mediated vasodilation. This makes it useful in cardiogenic shock, where improving cardiac output is the priority without substantially raising afterload. Its mild beta-2 activity can cause slight peripheral vasodilation, which helps offset any increase in myocardial oxygen demand from increased contractility. Dobutamine is typically preferred over agents with strong alpha-1 activity when the goal is to augment pump function rather than vasoconstrict.

• A. Dobutamine's dominant action is on beta-1, not beta-2, receptors.
• B. Dobutamine does not have clinically significant alpha-1 agonism or beta-2 antagonism.
• D. Significant beta-2 activity would cause more peripheral vasodilation than is typical for dobutamine.
• E. Pure alpha-1 agonism (like phenylephrine) would raise afterload and is not inotropic, worsening cardiogenic shock.

Isoproterenol is a nonselective beta-agonist (beta-1 and beta-2) with no alpha activity. Beta-1 stimulation increases heart rate and contractility, raising systolic pressure slightly, while beta-2 stimulation causes marked peripheral vasodilation, dropping diastolic pressure substantially. The net effect is a widened pulse pressure with a decrease in mean arterial pressure and a pronounced reflex-independent tachycardia, which is the classic hemodynamic signature of isoproterenol and distinguishes it from drugs with alpha-1 activity that raise diastolic pressure. This pattern is used experimentally and diagnostically to identify pure beta-agonist activity.

• A. Norepinephrine has strong alpha-1 activity and would raise, not lower, diastolic pressure and mean arterial pressure.
• B. Phenylephrine is a pure alpha-1 agonist and would raise both systolic and diastolic pressure with reflex bradycardia.
• C. Epinephrine has significant alpha-1 activity at higher doses and typically increases or maintains diastolic pressure rather than dropping it this much.
• E. Dobutamine is beta-1 selective with only mild beta-2 effect and does not cause this degree of diastolic pressure fall.

Amphetamine is an indirect sympathomimetic that enters presynaptic terminals via the norepinephrine transporter and is taken up into storage vesicles via the vesicular monoamine transporter (VMAT), where it displaces stored norepinephrine. The displaced norepinephrine then exits the neuron through reverse transport of the norepinephrine transporter, flooding the synapse independent of action potential-driven calcium influx. This mechanism explains both amphetamine's sympathomimetic effects and its tendency to deplete catecholamine stores with chronic use, contributing to tolerance (tachyphylaxis).

• A. Reserpine blocks VMAT, depleting catecholamine stores, but it does not actively promote reverse transport release the way amphetamine does.
• B. Cocaine blocks reuptake transporters directly but does not enter terminals or cause vesicular displacement and reverse transport.
• D. Phenylephrine is a direct-acting agonist that binds alpha-1 receptors itself, not an indirect releasing agent.
• E. Propranolol is a beta-receptor antagonist and has no sympathomimetic releasing action.

Tyramine is normally metabolized by monoamine oxidase in the gut wall and liver before reaching systemic circulation. In patients taking monoamine oxidase inhibitors like phenelzine, this first-pass degradation is blocked, allowing large amounts of tyramine to enter the bloodstream and act as an indirect sympathomimetic, entering sympathetic nerve terminals and displacing massive amounts of stored norepinephrine. The resulting surge of norepinephrine release causes a hypertensive crisis, which is why patients on MAOIs are counseled to avoid tyramine-rich foods such as aged cheeses, cured meats, and fermented products.

• A. Tyramine has weak direct receptor activity; its effects are mediated through norepinephrine release, not direct receptor binding.
• B. Phenelzine does not directly stimulate adrenergic receptors; its relevant action is MAO inhibition.
• C. MAOIs inhibit monoamine oxidase, not cytochrome P450 enzymes, and the mechanism is metabolic degradation, not absorption.
• D. Tyramine does not act primarily by blocking reuptake; its main action is promoting norepinephrine release.

Phenoxybenzamine is a haloalkylamine that forms a reactive carbonium ion intermediate, which covalently alkylates alpha-1 and alpha-2 receptors, producing irreversible, nonselective, non-competitive blockade. This long duration of action protects against catecholamine surges released during tumor manipulation in pheochromocytoma surgery. Because the blockade is irreversible, receptor function only recovers through synthesis of new receptors, giving a sustained effect even after the drug is cleared from plasma. This distinguishes it from reversible competitive antagonists like phentolamine and prazosin.

• A. Phenoxybenzamine does not block beta receptors; labetalol and carvedilol act at both receptor types.
• B. This describes metyrosine, a different drug sometimes used adjunctively, not the alpha-blocking mechanism.
• C. This describes reserpine, which depletes vesicular catecholamine stores rather than blocking receptors.
• D. This describes prazosin or tamsulosin, which are competitive and alpha-1 selective, not phenoxybenzamine.

Metoprolol is a beta-1 selective antagonist at low to moderate doses, preferentially blocking cardiac beta-1 receptors while relatively sparing beta-2 receptors in bronchial smooth muscle and hepatic/skeletal muscle tissue. This selectivity reduces the risk of bronchospasm in asthmatic patients and lessens interference with beta-2-mediated glycogenolysis and gluconeogenesis, which is important for recognizing and recovering from hypoglycemia in diabetics. Selectivity is relative and diminishes at higher doses, so caution is still warranted, but beta-1 selective agents remain preferred over nonselective agents in patients with reactive airway disease or diabetes.

• B. Carvedilol blocks beta-1, beta-2, and alpha-1 receptors and is not beta-1 selective, making it less favorable in reactive airway disease.
• C. Propranolol is a nonselective beta blocker that blocks both beta-1 and beta-2 receptors, risking bronchospasm and masking hypoglycemia.
• D. Timolol is a nonselective beta blocker, more commonly used topically for glaucoma, with the same selectivity limitations.
• E. Nadolol is also nonselective and carries the same risks of bronchoconstriction and blunted hypoglycemic counter-regulation.

Hypoglycemic warning symptoms such as tremor, tachycardia, palpitations, and anxiety are mediated largely by epinephrine acting on beta-1 and beta-2 adrenergic receptors as part of the sympathoadrenal counter-regulatory response. Nonselective beta blockers like propranolol block these receptors, blunting the adrenergic warning signs while sweating (a cholinergic response) may persist. This can delay recognition of hypoglycemia, particularly in insulin-dependent diabetics, increasing the risk of severe or prolonged hypoglycemia before it is noticed and treated. Beta-1 selective agents cause this effect to a lesser degree, but caution is still needed in diabetic patients on any beta blocker.

• A. Beta blockers act peripherally on adrenergic receptors, not centrally on hypothalamic glucose-sensing neurons.
• B. Beta blockade does reduce glycogenolysis contributing to prolonged hypoglycemia, but this does not explain the blunted warning symptoms, which are adrenergic in origin.
• C. Beta blockers do not significantly affect renal glucose handling; this is unrelated to symptom masking.
• D. Beta blockers do not meaningfully alter insulin sensitivity; this is not the mechanism of symptom masking.

Beta-2 receptors on bronchial smooth muscle normally mediate relaxation (bronchodilation) via Gs-coupled activation of adenylyl cyclase and increased intracellular cAMP. Nonselective beta blockers block beta-2 receptors along with beta-1 receptors, removing this bronchodilatory tone and allowing unopposed bronchoconstriction, which can precipitate severe bronchospasm in patients with reactive airway disease such as asthma. This is why nonselective beta blockers (propranolol, nadolol, timolol) are relatively contraindicated in asthma, and beta-1 selective agents are preferred when a beta blocker is necessary. Even beta-1 selective agents should be used cautiously, since selectivity is lost at higher doses.

• A. Beta blockers do not act on muscarinic receptors; this describes a different, unrelated mechanism of bronchoconstriction.
• C. Beta blockers do not act on alpha-1 receptors, and this is not the primary mechanism of beta blocker-induced bronchospasm.
• D. Beta blockers do not alter leukotriene receptor expression; this is unrelated to their pharmacologic mechanism.
• E. Bronchial smooth muscle tone is governed by beta-2 receptors, not beta-1 receptors, which predominate in the heart and kidney.

Essential tremor and performance anxiety-induced tremor are exacerbated by circulating catecholamines acting on beta-2 receptors in skeletal muscle, which increase the sensitivity of muscle spindles and enhance physiologic tremor. Propranolol, a nonselective beta blocker, blocks these peripheral beta-2 receptors, reducing the amplitude of tremor without requiring central nervous system sedation, making it useful for performance anxiety and essential tremor. It is typically taken as a single dose before the anxiety-provoking event. Unlike benzodiazepines, propranolol does not act on GABA receptors and does not cause sedation or dependence.

• A. Beta-1 receptors are located primarily in cardiac tissue and the kidney, not skeletal muscle, and are not the main mediator of tremor.
• B. This describes the mechanism of benzodiazepines, not propranolol, which does not act on GABA receptors.
• D. Propranolol has no significant alpha-1 blocking activity; that mechanism describes drugs like prazosin.
• E. Propranolol does not act on dopamine receptors; this describes the mechanism of antipsychotics, not beta blockers.

Chronic beta-receptor blockade leads to a compensatory increase in the number and sensitivity of beta-adrenergic receptors on the cell surface, a phenomenon similar to receptor upregulation seen with other chronic antagonist therapy. When the blocking drug is abruptly withdrawn, endogenous catecholamines act on this increased population of sensitized receptors, producing an exaggerated sympathetic response manifesting as rebound tachycardia, hypertension, and in patients with coronary disease, potentially myocardial ischemia or infarction. This is why beta blockers should be tapered gradually over 1 to 2 weeks rather than stopped abruptly. Patient education about medication adherence and gradual discontinuation is essential.

• B. Beta blockers do not deplete norepinephrine stores; that mechanism describes reserpine or guanethidine.
• C. Metoprolol does not have an active metabolite with sympathomimetic properties; this is not a recognized mechanism.
• D. Beta blocker withdrawal does not cause adrenal insufficiency; this describes a distinct endocrine disorder unrelated to receptor pharmacology.
• E. Tolerance to antihypertensive effect does not explain an acute hypertensive and tachycardic crisis upon drug cessation.

A tonic (Adie) pupil results from damage to postganglionic parasympathetic neurons in the ciliary ganglion, causing denervation supersensitivity of the iris sphincter muscarinic receptors. Dilute pilocarpine (0.1%), which is normally too weak to constrict a healthy pupil, produces exaggerated constriction in the affected eye due to upregulated muscarinic receptors, while the normal eye remains unaffected. This pharmacologic test distinguishes a tonic pupil from a third nerve palsy, where pilocarpine-induced constriction would require higher concentrations because the receptors are not supersensitive. The light-near dissociation (poor light reaction, better near response) also supports this diagnosis.

• A. Physiologic anisocoria would show a normal, non-supersensitive pupillary response to dilute pilocarpine in both eyes.
• B. Anticholinergic-induced mydriasis would not constrict with pilocarpine at all because muscarinic receptors are pharmacologically blocked.
• C. Horner syndrome causes miosis, not mydriasis, so it does not fit this presentation.
• D. Third nerve compression from an aneurysm typically also causes ptosis and extraocular motility deficits, and the affected pupil would not show denervation supersensitivity to dilute pilocarpine.

Chronic blockade of beta-1 receptors by an antagonist reduces receptor activation, and in compensation the cell increases the number (density) of beta-1 receptors expressed on the membrane, a phenomenon called upregulation. When the antagonist is abruptly withdrawn, there are now more receptors available for endogenous catecholamines to act on, producing an exaggerated sympathetic response such as rebound tachycardia and hypertension. This is why beta blockers (whether systemic or topical, since topical beta blockers can have systemic absorption) should be tapered rather than stopped abruptly. The opposite phenomenon, downregulation, occurs with chronic agonist exposure (e.g., beta-2 agonist tolerance in asthma).

• A. Downregulation occurs with chronic agonist (not antagonist) exposure and would blunt, not enhance, the sympathetic response upon withdrawal.
• B. Antagonist exposure does not convert receptors to a low-affinity state; receptor number changes, not affinity conformation, best explains withdrawal supersensitivity.
• C. Beta blockers like timolol act as competitive, reversible antagonists, not irreversible covalent binders.
• E. Supersensitivity after beta blocker withdrawal is due to increased receptor density, not depletion of presynaptic norepinephrine stores.

At normal doses, acetaminophen is mostly cleared by glucuronidation and sulfation, with a small fraction metabolized by CYP2E1 to the toxic intermediate NAPQI, which is normally detoxified by conjugation with glutathione. In overdose, glucuronidation and sulfation pathways are saturated, more acetaminophen is shunted through CYP2E1, and hepatic glutathione stores become depleted, allowing NAPQI to accumulate and cause centrilobular hepatic necrosis. N-acetylcysteine acts as a glutathione precursor (and direct glutathione substitute), replenishing glutathione stores so that NAPQI can again be safely conjugated and detoxified. It is most effective when given early, ideally within 8-10 hours of ingestion.

• A. Sulfation cofactor depletion is not the primary target restored by N-acetylcysteine in overdose treatment.
• B. CYP2E1 produces the toxic metabolite rather than detoxifying it; N-acetylcysteine does not act by increasing this enzyme.
• C. Methemoglobin reductase is relevant to methemoglobinemia treatment, not acetaminophen-induced hepatotoxicity.
• D. Glucuronidation capacity is not the limiting detoxification pathway restored by N-acetylcysteine; glutathione conjugation of NAPQI is.

Naloxone is a competitive antagonist at opioid receptors (mainly mu) with a relatively short half-life of about 30 to 90 minutes, which is typically shorter than the duration of action of the opioid being reversed, especially long-acting opioids or heroin's active metabolite morphine. As naloxone is cleared, the opioid that remains in the body can again occupy receptors and produce respiratory depression, requiring repeat dosing or a continuous infusion in overdose management. This is why patients reversed with naloxone must be monitored and may need redosing rather than a single dose. The competitive nature of the antagonism means that higher opioid concentrations can also overcome naloxone's blockade as its level falls.

• A. Naloxone binds reversibly and competitively to opioid receptors, not irreversibly.
• B. Naloxone's mechanism of reversal is competitive antagonism; relative receptor affinity/potency is not what explains the timing of recurrent toxicity here.
• D. Naloxone does not act through hepatic enzyme induction to clear opioid metabolites; the recurrence is due to its own short duration relative to the opioid.
• E. Naloxone is a full competitive antagonist with no intrinsic agonist activity, not a partial agonist.

Flumazenil is a competitive antagonist at the benzodiazepine binding site on the GABA-A receptor. In patients who are benzodiazepine-dependent or co-ingested with another proconvulsant (e.g., tricyclic antidepressants), abruptly reversing the chronic GABA-A potentiation removes tonic inhibitory tone, unmasking a hyperexcitable state and precipitating withdrawal seizures. This is why flumazenil is avoided in chronic benzodiazepine users and in mixed overdoses with proconvulsant drugs. The seizures result from rebound neuronal excitability, not a direct excitatory action of flumazenil itself.

• A. Flumazenil has no direct agonist activity at NMDA or other excitatory receptors; its action is purely antagonistic at the GABA-A benzodiazepine site.
• B. Flumazenil acts specifically at the GABA-A receptor benzodiazepine site and does not bind GABA-B receptors.
• C. Flumazenil decreases, not increases, chloride conductance by blocking benzodiazepine potentiation of GABA-A receptors.
• E. Flumazenil does not significantly affect cytochrome P450 enzymes or alprazolam metabolism.

Ethylene glycol (found in antifreeze) is metabolized by alcohol dehydrogenase into toxic metabolites, including glycoaldehyde and ultimately oxalic acid, which forms calcium oxalate crystals and causes severe anion gap metabolic acidosis and renal injury. Fomepizole is a competitive inhibitor of alcohol dehydrogenase with much higher affinity than ethanol or ethylene glycol, blocking the formation of these toxic metabolites. This allows the parent alcohol to be excreted unchanged or slowly metabolized by other pathways. Fomepizole has largely replaced ethanol as first-line therapy because it does not cause CNS depression or require serum level monitoring.

• A. Fomepizole does not chelate oxalate or any metabolite; its action is purely enzymatic inhibition upstream.
• B. Aldehyde dehydrogenase inhibition describes the mechanism of disulfiram, not fomepizole.
• C. Fomepizole works by blocking toxic metabolite formation, not by promoting osmotic diuresis.
• D. Fomepizole inhibits, rather than induces, the relevant metabolic pathway and does not act on CYP2E1.

Serotonin syndrome occurs when excess serotonin accumulates at central and peripheral synapses, most dangerously when a serotonin reuptake inhibitor (such as fluoxetine) is combined with a monoamine oxidase inhibitor (such as phenelzine), because MAO is the primary enzyme that degrades serotonin, and its inhibition combined with blocked reuptake dramatically raises synaptic serotonin levels. The classic triad is autonomic instability (hyperthermia, tachycardia, hypertension), neuromuscular abnormalities (clonus, hyperreflexia, tremor), and altered mental status (agitation). Fluoxetine's long half-life and active metabolite mean a prolonged washout period is required before starting an MAOI, or vice versa, to avoid this interaction. Treatment includes discontinuing both agents, supportive cooling, benzodiazepines, and cyproheptadine (a serotonin antagonist) in severe cases.

• A. Tyramine reactions occur with MAOIs and tyramine-containing foods causing a hypertensive crisis, a distinct mechanism from serotonin syndrome.
• B. This combination increases, not depletes, available synaptic serotonin.
• D. Fluoxetine and phenelzine increase serotonin levels; they do not antagonize serotonin receptors.
• E. SSRIs do not meaningfully affect dopamine reuptake, and the syndrome described is specifically serotonin-mediated.

Ethanol is normally metabolized sequentially by alcohol dehydrogenase to acetaldehyde, and then by aldehyde dehydrogenase to acetate, which is further metabolized. Metronidazole, like disulfiram, inhibits aldehyde dehydrogenase, blocking the second step and causing toxic acetaldehyde to accumulate in the blood after alcohol consumption. Elevated acetaldehyde produces the characteristic flushing, headache, nausea, vomiting, and tachycardia seen in this patient, a reaction known as the disulfiram-like or antabuse-like effect. Patients prescribed metronidazole should be counseled to avoid alcohol during treatment and for several days afterward due to the drug's prolonged half-life.

• A. Induction of CYP2E1 would increase acetaldehyde production via a different pathway and is not the described mechanism of metronidazole.
• B. Metronidazole does not inhibit alcohol dehydrogenase; it acts further downstream in ethanol metabolism.
• C. Acetyl-CoA synthetase is not the enzyme targeted by metronidazole in this interaction.
• E. Monoamine oxidase inhibition describes drug interactions like the tyramine reaction with MAOIs, not the metronidazole-alcohol interaction.

Malignant hyperthermia is caused by a mutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor, a calcium release channel in the sarcoplasmic reticulum. Exposure to volatile anesthetics (such as sevoflurane) or succinylcholine triggers massive, uncontrolled calcium release into the cytoplasm, causing sustained muscle contraction, heat production, hypermetabolism, and rhabdomyolysis. Clinical features include hypercarbia, tachycardia, muscle rigidity, and rapidly rising temperature. Treatment is dantrolene, which blocks the ryanodine receptor and inhibits further calcium release.

• A. This mechanism describes a toxic effect on liver mitochondria, unrelated to the skeletal muscle pathology seen here.
• C. Pseudocholinesterase deficiency causes prolonged paralysis after succinylcholine, not hyperthermia or rigidity.
• D. Histamine release from succinylcholine typically causes flushing or bronchospasm, not sustained rigidity and hyperthermia.
• E. This describes myasthenia gravis, which causes weakness, not a hypermetabolic crisis with rigidity.

At steady state, the rate of drug administration equals the rate of drug elimination, so the maintenance dosing rate equals clearance multiplied by the target steady-state concentration, divided by bioavailability. Here, 10 L/hr multiplied by 4 mg/L equals 40 mg/hr, and because the infusion is intravenous, bioavailability is 1, so no adjustment is needed. This relationship explains why patients with reduced clearance (for example, due to renal or hepatic impairment) require lower maintenance doses to avoid drug accumulation.

• B. This rate is four times the required dose and would substantially exceed the therapeutic target.
• C. This rate is one-fourth the required dose and would produce a steady-state concentration below target.
• D. This rate is twice the required dose and would produce plasma levels above the target, risking toxicity.
• E. This rate is half the required dose and would under-treat the patient.

For a drug eliminated by first-order kinetics, the time required to reach steady-state plasma concentration depends solely on the drug's half-life, since it takes approximately four to five half-lives to reach steady state regardless of the infusion rate or dose administered. Changing the infusion rate changes the magnitude of the steady-state concentration achieved, but not the time needed to get there, because half-life and time to steady state are both governed by clearance and volume of distribution, which are unchanged between the two patients. This principle underlies why doubling a maintenance infusion rate raises the eventual plateau concentration without speeding up how quickly that plateau is reached.

• A. Infusion rate does not slow the time to steady state; only half-life determines this.
• B. A higher infusion rate increases the steady-state concentration achieved, not the speed at which steady state is reached.
• C. Steady state is always eventually reached during constant-rate infusion as long as clearance remains constant; the infusion rate affects only the concentration achieved.
• E. While patient A does reach a higher steady-state concentration, the time to reach that plateau is the same for both patients.

Salicylate is a weak acid that exists in equilibrium between its protonated (nonionized) and deprotonated (ionized) forms, with only the nonionized form able to passively diffuse across renal tubular cell membranes back into the bloodstream. Alkalinizing the urine with sodium bicarbonate raises urine pH above the drug's pKa, favoring the ionized form, which becomes trapped within the tubular lumen and is excreted in the urine rather than reabsorbed. This ion trapping phenomenon is the pharmacologic basis for using urinary alkalinization to accelerate elimination in salicylate overdose. The same principle applies in reverse, using urinary acidification to trap and eliminate weak bases.

• A. Urine pH changes do not alter plasma protein binding of the drug.
• B. Urinary alkalinization acts in the kidney tubule, not on hepatic metabolic enzymes.
• C. Alkalinization does not inhibit active tubular secretion; in fact, enhanced ion trapping increases net elimination.
• E. Urinary alkalinization does not meaningfully change glomerular filtration rate; its effect is on tubular reabsorption, not filtration.

Volume of distribution is an apparent value relating the amount of drug in the body to its measured plasma concentration, and it can exceed actual physiologic body water when a drug partitions heavily into tissues, leaving very little in the plasma to sample. A lipophilic drug like drug X distributes extensively into adipose tissue and other tissue compartments, producing a very low plasma concentration relative to total body drug content and thus a very high calculated Vd. In contrast, a drug extensively bound to plasma proteins, like drug Y, remains largely confined to the vascular compartment, producing a Vd that approximates plasma volume.

• A. Active transport into red blood cells or renal excretion patterns are not the standard explanations for markedly elevated or low volumes of distribution.
• B. This reverses the pairing: extensive plasma protein binding restricts a drug to the vascular space, giving a low Vd, not a high one, while tissue sequestration gives a high Vd.
• D. First-pass metabolism affects bioavailability of orally administered drugs, not the volume of distribution calculated after intravenous dosing.
• E. Half-life depends on both clearance and volume of distribution together; it does not by itself explain why one drug has a much larger apparent Vd.

A rightward shift in the agonist dose-response curve, with an increased EC50 (higher agonist concentration needed for 50% maximal effect) but an unchanged maximal effect (Emax), is the classic signature of a competitive, reversible antagonist. Because the antagonist competes with the agonist for the same binding site, increasing the agonist concentration can outcompete the antagonist and still achieve the same maximal response, just requiring a higher dose to do so. In contrast, noncompetitive or irreversible antagonists reduce the maximal achievable response because they remove functional receptors from the available pool regardless of agonist concentration.

• A. A partial agonist alone (without the full agonist) would itself produce a lower Emax than the full agonist, rather than simply shifting the curve rightward while preserving the full agonist's Emax.
• C. Noncompetitive antagonism reduces Emax because it impairs receptor function (or signal transduction) in a way that added agonist cannot overcome.
• D. A physiologic antagonist acting through an unrelated receptor and pathway would not produce this clean dose-dependent rightward shift with preserved Emax, which depends on direct competition at the same binding site.
• E. Irreversible antagonists reduce the maximal achievable response because covalently bound receptors cannot be displaced even by high agonist concentrations.

Organophosphates (found in many pesticides) covalently and irreversibly phosphorylate the serine hydroxyl group in the active site of acetylcholinesterase, preventing breakdown of acetylcholine at synapses and neuromuscular junctions. The resulting cholinergic excess produces the DUMBELSS toxidrome: diarrhea/diaphoresis, urination, miosis, bradycardia/bronchorrhea, emesis, lacrimation, salivation, and sweating, along with nicotinic effects like fasciculations and weakness. The garlic-like odor and occupational exposure strongly support organophosphate toxicity. Early treatment with atropine and pralidoxime is critical before the enzyme-inhibitor complex 'ages' into a permanent form.

• B. This describes a reversible mechanism, unlike the irreversible inhibition caused by organophosphates.
• C. Nicotinic blockade would cause muscle paralysis, not the combination of fasciculations with muscarinic signs described here.
• D. Alpha-1 agonism would cause hypertension and mydriasis, not miosis and hypotension.
• E. MAO inhibition does not produce miosis, bradycardia, or bronchorrhea; it typically causes sympathetic overactivity.

Pralidoxime is a nucleophile that reactivates acetylcholinesterase by cleaving the phosphate-enzyme bond formed by the organophosphate, restoring enzymatic function, particularly at the neuromuscular junction. Over time, the phosphorylated enzyme undergoes a process called 'aging,' in which it loses an alkyl group and the phosphorus-enzyme bond becomes resistant to hydrolysis by pralidoxime. Once aging has occurred, the enzyme is permanently inactivated and new enzyme must be synthesized, which can take weeks. This is why pralidoxime is most effective when given within hours of exposure, before significant aging has taken place.

• A. Nicotinic receptor density does not change acutely and is not the basis for the urgency of pralidoxime therapy.
• B. Organophosphate redistribution does not determine whether the enzyme-inhibitor complex can be reactivated.
• D. Aging affects the existing enzyme protein, not gene transcription, and transcription is not permanently silenced.
• E. Pralidoxime's efficacy window is determined by enzyme aging, not by its own metabolism at the synapse.

Atropine is a competitive muscarinic receptor antagonist and is the first-line treatment for the muscarinic symptoms of organophosphate poisoning, rapidly reversing bronchorrhea, bronchospasm, bradycardia, and excessive secretions, which are the most immediately life-threatening features. It should be titrated to drying of secretions and improvement in bronchospasm and does not address nicotinic effects such as muscle weakness or fasciculations. Pralidoxime is often given afterward or concurrently to address both muscarinic and nicotinic effects by reactivating acetylcholinesterase, but atropine takes priority because it acts faster on the life-threatening muscarinic crisis. Supportive airway management should also be ensured throughout.

• A. Physostigmine is an acetylcholinesterase inhibitor and would exacerbate the cholinergic crisis.
• C. Neostigmine is itself an acetylcholinesterase inhibitor and would worsen cholinergic toxicity.
• D. Succinylcholine is metabolized by plasma cholinesterase, which is also inhibited in organophosphate poisoning, leading to prolonged paralysis; it has no role here.
• E. Pralidoxime reactivates the enzyme but acts more slowly and is typically given after or with atropine, not as the immediate priority for muscarinic crisis.

Atropine competitively blocks muscarinic acetylcholine receptors throughout the body, producing a predictable constellation of antimuscarinic effects: mydriasis (loss of parasympathetic pupillary constriction), tachycardia (loss of vagal tone on the sinoatrial node), urinary retention (decreased detrusor contraction), dry mouth (decreased salivary secretion), and hyperthermia (decreased sweat gland activity, impairing heat dissipation). This adverse effect profile is classically remembered as 'dry as a bone, blind as a bat, red as a beet, hot as a hare, and mad as a hatter.' These effects are dose-dependent and reversible with discontinuation or, in severe cases, physostigmine.

• A. Direct alpha-1 agonism would cause vasoconstriction and hypertension, not the combination of findings described.
• B. Acetylcholine depletion is not atropine's mechanism; atropine blocks receptors rather than affecting neurotransmitter stores.
• C. Norepinephrine reuptake inhibition would cause sympathetic overactivity but would not cause mydriasis, dry mouth, or urinary retention through a cholinergic mechanism.
• E. Sodium channel blockade would not produce this specific pattern of mydriasis, dry mouth, and urinary retention.

Haloperidol causes drug-induced parkinsonism by blocking striatal D2 receptors, which disrupts the normal balance between dopaminergic (inhibitory) and cholinergic (excitatory) signaling in the striatum, leading to relative cholinergic excess. Benztropine is a centrally acting muscarinic receptor antagonist that blocks this excess cholinergic activity in the striatum, restoring the dopamine-acetylcholine balance and improving tremor and rigidity. This mechanism is also useful in idiopathic Parkinson's disease, where cholinergic interneurons become relatively overactive as dopaminergic neurons degenerate. Benztropine does not affect dopamine receptors directly and does not reverse the D2 blockade caused by antipsychotics.

• A. COMT inhibitors like entacapone affect dopamine metabolism but this is not benztropine's mechanism.
• B. Benztropine does not increase dopamine synthesis and is unrelated to levodopa metabolism.
• C. Benztropine blocks muscarinic, not nicotinic, receptors; nicotinic blockade is not relevant to its antiparkinsonian effect.
• E. Benztropine does not act on dopamine receptors; it is a muscarinic antagonist, not a dopamine agonist.

Ipratropium and tiotropium are quaternary ammonium antimuscarinic agents that block M3 muscarinic receptors on airway smooth muscle, preventing acetylcholine released from vagal parasympathetic fibers from causing bronchoconstriction and mucus secretion. Because they are poorly absorbed systemically when given by inhalation, their effects are largely confined to the lungs, minimizing systemic antimuscarinic adverse effects such as dry mouth, tachycardia, and urinary retention. This selective pulmonary action makes them a cornerstone of COPD management, often used alone or combined with beta-2 agonists. Tiotropium has a longer duration of action than ipratropium due to slower dissociation from M3 receptors.

• A. This describes the mechanism of leukotriene receptor antagonists like montelukast, used in asthma, not COPD bronchodilators like ipratropium.
• B. This describes the mechanism of beta-2 agonists like albuterol, not antimuscarinic agents.
• C. This describes the mechanism of mast cell stabilizers like cromolyn, not antimuscarinic bronchodilators.
• D. This describes the mechanism of roflumilast, used in COPD for its anti-inflammatory effect, not ipratropium or tiotropium.

Oxybutynin is a muscarinic receptor antagonist that relaxes detrusor smooth muscle to reduce involuntary bladder contractions in overactive bladder, but it also blocks muscarinic receptors elsewhere in the body. In elderly patients, it crosses the blood-brain barrier and can cause central antimuscarinic effects such as confusion and cognitive impairment, along with peripheral effects including tachycardia, dry mouth, blurred vision, and constipation. Elderly patients are particularly susceptible to anticholinergic toxicity due to decreased cholinergic reserve and increased blood-brain barrier permeability, making oxybutynin and similar drugs part of the anticholinergic burden to avoid in this population per Beers criteria. Alternative agents with less central penetration, such as trospium, may be preferred in older adults.

• A. Beta-2 blockade would not explain the combination of confusion, dry mouth, and constipation; oxybutynin does not act on adrenergic receptors.
• B. 5-HT3 agonism would promote nausea and vomiting, not constipation, and is unrelated to oxybutynin's mechanism.
• C. D2 blockade would cause extrapyramidal symptoms, not this combination of antimuscarinic findings.
• D. Acetylcholinesterase inhibition would increase cholinergic activity and cause the opposite effects (e.g., salivation, bradycardia).

Epinephrine has affinity for beta-1, beta-2, and alpha-1 adrenergic receptors, but its effects are dose-dependent because beta receptors are activated at lower concentrations than alpha-1 receptors. At low to moderate doses, beta-1-mediated increased heart rate and contractility and beta-2-mediated bronchodilation and vasodilation in skeletal muscle predominate. At higher doses, alpha-1-mediated vasoconstriction in skin, mucosa, and splanchnic beds becomes more prominent, which can raise peripheral vascular resistance and blood pressure. This dose-dependent receptor selectivity is why epinephrine is the drug of choice in anaphylaxis, providing bronchodilation and cardiac stimulation while also countering vasodilation and vascular permeability at higher local or systemic concentrations.

• A. Epinephrine does not cross the blood-brain barrier appreciably due to its polarity, and this is not the basis for dose-dependent receptor effects.
• B. Epinephrine is not inactivated by protein binding at low doses; it remains pharmacologically active and binds adrenergic receptors directly.
• C. Epinephrine does not act on muscarinic receptors; it is an adrenergic agonist.
• E. COMT metabolism is not selective for alpha receptors and does not explain this dose-dependent receptor shift.